097 Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23–receptor
用户EVlzWziI7lqQ
2个月前
83
10
已完结
1. 系统已在2025-12-21 21:09:50对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.jid.2025.10.101
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0022202X25029331
其他信息:
出版社: Elsevier BV
作者: MJ Gooderham; E Lain; R Bissonette; Y Huang; C Lynde; M Hoffman; E Song; J Rubens; J Obeid; RB Warren
